# Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

> **NCT01743118** · PHASE1 · COMPLETED · sponsor: **Circassia Limited** · enrollment: 24 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** SPS4251 Ointment
- **DRUG:** Placebo
- **DRUG:** Daivonex® ointment

## Key facts

- **NCT ID:** NCT01743118
- **Lead sponsor:** Circassia Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743118, "Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01743118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*